192 related articles for article (PubMed ID: 19398128)
1. p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
Tsai-Turton M; Santillan A; Lu D; Bristow RE; Chan KC; Shih IeM; Roden RB
Gynecol Oncol; 2009 Jul; 114(1):12-7. PubMed ID: 19398128
[TBL] [Abstract][Full Text] [Related]
2. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
[TBL] [Abstract][Full Text] [Related]
3. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
4. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells.
Vogl FD; Stickeler E; Weyermann M; Köhler T; Grill HJ; Negri G; Kreienberg R; Runnebaum IB
Oncology; 1999 Nov; 57(4):324-9. PubMed ID: 10575320
[TBL] [Abstract][Full Text] [Related]
5. p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.
Häfner N; Nicolaus K; Weiss S; Frey M; Diebolder H; Rengsberger M; Dürst M; Runnebaum IB
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1207-10. PubMed ID: 23576021
[TBL] [Abstract][Full Text] [Related]
6. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
7. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
8. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
[No Abstract] [Full Text] [Related]
9. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
Vogl FD; Frey M; Kreienberg R; Runnebaum IB
Br J Cancer; 2000 Nov; 83(10):1338-43. PubMed ID: 11044359
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
11. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
12. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
Katchman BA; Barderas R; Alam R; Chowell D; Field MS; Esserman LJ; Wallstrom G; LaBaer J; Cramer DW; Hollingsworth MA; Anderson KS
Proteomics Clin Appl; 2016 Jul; 10(7):720-31. PubMed ID: 27121307
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
[TBL] [Abstract][Full Text] [Related]
14. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
[TBL] [Abstract][Full Text] [Related]
16. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
[TBL] [Abstract][Full Text] [Related]
17. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Fortner RT; Damms-Machado A; Kaaks R
Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
20. A rapid, accurate and robust particle-based assay for the simultaneous screening of plasma samples for the presence of five different anti-cytokine autoantibodies.
Guldager DKR; von Stemann JH; Larsen R; Bay JT; Galle PS; Svenson M; Ullum H; Hansen MB
J Immunol Methods; 2015 Oct; 425():62-68. PubMed ID: 26080061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]